A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma
University of Ulm
University of Ulm
University of Pittsburgh
Hartford Hospital
Hartford Hospital
Icahn School of Medicine at Mount Sinai
University Health Network, Toronto
National Cancer Institute (NCI)
Emory University
Radiation Therapy Oncology Group
University of Alabama at Birmingham
Northwestern University
National University Hospital, Singapore
University Health Network, Toronto
Herlev Hospital